Novartis AG reported strong Q2 results driven by a 43.4% year-on-year sales increase in its oncology drug Pluvicto, reaching $651 million. Despite a decline in sales of its heart failure drug Entresto, the company reaffirmed its full-year 2026 guidance, expecting net sales growth in the low single digits. This robust oncology performance led an analyst to upgrade Novartis stock from hold to buy, signaling confidence in the company's future growth prospects.
The global cancer biomarkers market is projected to grow from $25.9 billion in 2026 to $37.8 billion by 2035, fueled by rising cancer cases and advances in precision oncology such as next-generation sequencing and AI diagnostics. Biomarkers help tail...
Novartis is set to report its Q2 earnings with analysts expecting an EPS of $2.17 and revenue of $14.07 billion, following a tough Q1 affected by major patent expirations. Despite revenue challenges, the company maintained strong cash flow of $3.30 b...
